$424.5 M

ACHN Mkt cap, 18-Mar-2019
Achillion Pharmaceuticals Net income (FY, 2018)-70.3 M
Achillion Pharmaceuticals EBIT (FY, 2018)-75.9 M
Achillion Pharmaceuticals Cash, 31-Dec-201849.8 M
Achillion Pharmaceuticals EV374.8 M

Achillion Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

66.1m15.0m

Revenue growth, %

(77%)

R&D expense

46.7m53.5m56.6m59.2m65.1m50.1m

General and administrative expense

12.7m15.9m24.7m20.7m24.5m23.9m

Operating expense total

59.5m69.4m81.2m79.9m89.6m75.9m

EBIT

(59.5m)(69.4m)(15.1m)(64.9m)(89.6m)(75.9m)

EBIT margin, %

(23%)(432%)

Interest expense

52.0k37.0k55.0k68.0k50.0k36.0k

Interest income

582.0k455.0k1.2m3.2m4.4m5.7m

Net Income

(58.9m)(69.0m)(5.0m)(61.7m)(85.2m)(70.3m)

Achillion Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

33.5m73.7m81.7m77.3m43.5m49.8m

Accounts Receivable

223.2m

Inventories

2.5m1.9m2.7m3.5m

Current Assets

124.8m154.9m462.6m382.5m303.9m275.4m

PP&E

1.3m1.7m2.8m2.1m

Total Assets

162.4m156.8m464.5m413.9m337.6m277.9m

Accounts Payable

4.6m6.4m4.1m7.0m5.3m2.3m

Short-term debt

291.0k195.0k223.0k351.0k170.0k131.0k

Current Liabilities

9.4m13.1m14.7m14.0m12.9m11.8m

Long-term debt

56.0k279.0k231.0k301.0k131.0k

Total Debt

347.0k474.0k454.0k652.0k301.0k131.0k

Total Liabilities

9.5m14.9m14.4m13.1m11.8m

Additional Paid-in Capital

534.5m599.8m905.3m916.6m927.4m

Retained Earnings

(381.7m)(450.7m)(455.7m)(517.4m)(602.7m)(672.9m)

Total Equity

153.0m143.5m449.6m399.5m324.5m266.0m

Debt to Equity Ratio

0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x

Financial Leverage

1.1 x1.1 x1 x1 x1 x1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

25.6m34.1m33.3m39.6m46.7m61.7m150.4m58.7m33.8m40.4m43.1m35.4m52.1m36.9m35.1m36.3m

Current Assets

141.9m142.6m133.6m128.7m255.6m249.5m465.3m443.0m429.1m411.8m383.4m355.2m327.0m309.5m291.9m286.4m

PP&E

1.2m1.4m1.3m1.6m1.9m1.9m2.4m3.0m3.1m3.3m3.1m3.0m2.7m2.6m2.4m

Total Assets

176.1m148.0m135.2m130.6m279.4m266.1m479.5m448.7m432.4m415.2m393.4m376.9m360.4m315.6m302.8m289.2m

Accounts Payable

4.8m3.6m2.0m2.6m8.0m11.5m4.9m6.6m5.8m5.4m4.1m3.0m8.1m2.4m1.4m1.6m

Short-term debt

326.0k256.0k164.0k110.0k213.0k216.0k219.0k227.0k230.0k234.0k316.0k259.0k201.0k151.0k153.0k156.0k

Current Liabilities

11.5m9.5m9.2m11.0m13.0m23.8m49.5m13.5m12.8m13.8m10.6m14.0m14.4m8.1m8.1m8.6m

Long-term debt

110.0k400.0k345.0k288.0k173.0k114.0k55.0k243.0k207.0k169.0k92.0k53.0k13.0k

Total Debt

436.0k256.0k164.0k110.0k613.0k561.0k507.0k400.0k344.0k289.0k559.0k466.0k370.0k243.0k206.0k169.0k

Total Liabilities

11.6m9.5m9.2m11.0m13.4m24.2m49.8m13.8m13.1m14.0m11.0m14.3m14.7m8.3m8.2m8.7m

Additional Paid-in Capital

532.6m536.1m539.3m548.6m735.8m740.8m902.3m908.2m911.1m913.8m919.8m922.7m925.1m931.1m935.3m936.9m

Retained Earnings

(368.3m)(397.8m)(413.4m)(429.1m)(469.9m)(498.9m)(472.7m)(473.8m)(492.3m)(513.0m)(537.6m)(560.1m)(579.5m)(623.2m)(640.4m)(656.3m)

Total Equity

164.4m138.4m126.0m119.6m266.0m241.9m429.7m434.9m419.3m401.2m382.3m362.6m345.7m307.3m294.6m280.5m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1 x1 x1 x1 x1 x1 x1 x1 x1 x

Achillion Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(58.9m)(69.0m)(5.0m)(61.7m)(85.2m)(70.3m)

Depreciation and Amortization

399.0k489.0k694.0k955.0k1.1m1.2m

Accounts Receivable

Inventories

(104.0k)575.0k(837.0k)(721.0k)

Accounts Payable

315.0k1.8m(2.3m)2.7m(1.6m)(2.9m)

Cash From Operating Activities

(53.6m)(55.5m)5.6m(65.7m)(59.5m)(62.0m)

Purchases of PP&E

(408.0k)(947.0k)(704.0k)(2.5m)(626.0k)(515.0k)

Cash From Investing Activities

(65.0m)43.3m(298.7m)60.7m26.0m66.3m

Long-term Borrowings

(350.0k)(313.0k)(249.0k)(246.0k)(351.0k)(170.0k)

Cash From Financing Activities

133.6m52.4m301.1m520.0k(262.0k)2.0m

Interest Paid

46.0k35.0k50.0k46.0k52.0k37.0k

Achillion Pharmaceuticals Ratios

USDY, 2018

EV/EBIT

-4.9 x

EV/CFO

-6 x

Financial Leverage

1 x
Report incorrect company information

Achillion Pharmaceuticals Employee Rating

3.55 votes
Culture & Values
4.0
Work/Life Balance
4.3
Senior Management
3.5
Salary & Benefits
3.1
Career Opportunities
3.5
Source